🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Oral cavity cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited
2026-10-26

Phase III Xevinapant plus radiotherapy shows benefit for high‑risk, cisplatin‑ineligible locally advanced head‑and‑neck cancer, including oral cavity tumors.

  1. Xevinapant (Debio 1143) combined with intensity‑modulated radiotherapy improved outcomes versus placebo in resected, locally advanced, high‑risk SCCHN patients who could not receive cisplatin.
    Provides a new, non‑cisplatin option for patients with oral cavity cancer who are unsuitable for standard chemotherapy, potentially improving survival and disease control. NCT05386550
  2. A global call urges accelerated oral cancer prevention and early detection efforts.
    Early identification of oral cavity lesions dramatically increases cure rates and reduces the need for extensive treatment. PMID:41643692
  3. Smokeless tobacco use is strongly associated with the development of oral cavity cancer worldwide.
    Eliminating this modifiable risk factor can markedly lower incidence and improve public‑health outcomes. PMID:41534101
  4. Recent studies challenge previously assumed links between the oral microbiome and cancer development.
    Refining our understanding of microbiome‑cancer interactions may open new preventive or therapeutic avenues. PMID:41289425
  5. US drug labels for oral cavity cancer have been recently updated.
    Label changes reflect the latest safety and usage information, but do not constitute new drug approvals. US drug label updates

What to watch next

💛 If you cannot receive cisplatin, the new Xevinapant‑radiotherapy regimen may offer a safer, effective treatment option. Detecting oral lesions early and avoiding smokeless tobacco are the most powerful steps you can take to prevent oral cavity cancer.

Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel HypersensitivityNCT03598426 · results posted 2026-06-09 · Loma Linda University · 90 people · tests Dexamethasone A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)NCT05456191 · results posted 2026-05-27 · Novartis Pharmaceuticals · 568 people · tests Asciminib, Nilotinib Evaluation in the Treatment of Neuropathic Pain Post Breast SurgeryNCT03794388 · results posted 2026-05-05 · Institut Cancerologie de l'Ouest · 140 people · tests Capsaicin, Pregabalin Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisNCT04472598 · results posted 2026-03-23 · AbbVie · 252 people · tests Placebo for Navitoclax, Ruxolitinib, Navitoclax Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)NCT05386550 · results posted 2026-02-19 · EMD Serono Research & Development Institute, Inc. · 166 people · tests Xevinapant, IMRT, Placebo LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyNCT01856478 · results posted 2026-01-12 · Boehringer Ingelheim · 340 people · tests Methotrexate, Afatinib Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104 · results posted 2025-10-31 · Jazz Pharmaceuticals · 3 people · tests GWP42003-P
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Time to act: a global call for oral cancer prevention and early detection.Lancet Oncol 2026 · PMID 41643692 Smokeless Tobacco and Oral Cancer in Global Perspective.N Engl J Med 2026 · PMID 41534101 Studies Challenge Cancer-Microbiome Links.Cancer Discov 2026 · PMID 41289425 Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance.Cell 2025 · PMID 41138728
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow oral cavity cancer and get a note on your phone with the new trials and papers.

🔔 Follow oral cavity cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy